Syngene International shares plunge 10% after Q4 results; CEO expects FY26 revenue growth in early teens

The company reported a net profit of ₹189 crore in the January-March period of the last fiscal year.

Total income rose to ₹1,037 crore for the fourth quarter as against ₹933 crore logged in the year-ago period, Syngene International said in a regulatory filing.

For the year ended March 31, 2025, Syngene reported a net profit of ₹496 crore as against ₹510 crore in FY24.

Total income rose to ₹3,714 crore for the fourth quarter as against ₹3,579 crore in the 2023-24 fiscal year.

The company said its board, which met on Wednesday, recommended a final dividend of ₹1.25 per share of ₹10 each for the 2024-25 financial year.

"The full-year results, led by reported revenue growth of 4%, are in line with our January guidance, reflecting a resilient performance in a challenging year. After a muted first half, driven by a sectoral downturn in US biotech funding, we are encouraged to see a return to growth in the second half of the year," Syngene International MD and CEO Peter Bains stated.

Looking at the year ahead, while the wider global market dynamics remain uncertain, the company expects the business momentum to continue with pipeline build in both small and large molecules, supported by new pilot programmes and conversion of existing pilots in discovery services.

"On an underlying basis for FY26, we expect revenue growth in the early teens, reflecting a broad-based growth across research, development, and manufacturing services," Bains said.

Adjusted for inventory balancing in large-molecule commercial manufacturing at the client level, the reported revenue growth is likely to be in the mid-single digits, the CEO added.

About Syngene International

Syngene is a contract research, development, and manufacturing organisation (CRDMO) that provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies.

Incorporated in 1993, Syngene is listed separately on the Indian stock exchanges – NSE and BSE.

"With a unique business model, a talent pool of 5656 scientists, scientific expertise across new therapeutic modalities, an experienced management team, and an independent board committee, Syngene works for clients around the globe, delivering innovation that benefits human and animal health," per the company's website.